News Center

TOT BIOPHARM was awarded as "the best investment case of biomedicine of the year".

发布时间:2019-08-02

On April 10, 2019, sponsored by the HaoYue capital, the theme of "broken", "the third ZhuoYueBang health investment summit" held in intercontinental pudong Shanghai, more than 400 well-known investment funds, from well-known enterprises, listed companies in the field of health care, industrial higher-ups and authoritative media attended the summit. At the meeting, the list of "2019 third medical health investment zhuoyuebang" was officially released, and TOT was awarded as "the best investment case of the year in biomedicine".

"A1 healthcare investment excellence list" is a ranking for healthcare sector, tracking the development and changes of Chinese healthcare enterprises and healthcare investment institutions. It is the third consecutive year for the ranking to be released in 2019, and has become a highly recognized annual authoritative list in the industry. According to the public information, the valuation of the 27 enterprises on the list in the first two sessions exceeded 204.2 billion yuan, among which: 3 listed in the IPO soon after the list, all of which were the leading enterprises in the segment.

On April 10, 2019, sponsored by the HaoYue capital, the theme of "broken", "the third ZhuoYueBang health investment summit" held in intercontinental pudong Shanghai, more than 400 well-known investment funds, from well-known enterprises, listed companies in the field of health care, industrial higher-ups and authoritative media attended the summit. At the meeting, the list of "2019 third medical health investment zhuoyuebang" was officially released, and TOT was awarded as "the best investment case of the year in biomedicine".

"A1 healthcare investment excellence list" is a ranking for healthcare sector, tracking the development and changes of Chinese healthcare enterprises and healthcare investment institutions. It is the third consecutive year for the ranking to be released in 2019, and has become a highly recognized annual authoritative list in the industry. According to the public information, the valuation of the 27 enterprises on the list in the first two sessions exceeded 204.2 billion yuan, among which: 3 listed in the IPO soon after the list, all of which were the leading enterprises in the segment.

After the selection of "authoritative judges, one vote per family" real-name voting, TOT successfully won the "2019 best biomedical investment case award", which is the industry's recognition and affirmation of the development of TOT in recent years. In the future, TOT will adhere to the business philosophy of "balance between humanity and science and technology", continue to innovate and develop, and make a contribution to China's biomedical industry.After the selection of "authoritative judges, one vote per family" real-name voting, TOT successfully won the "2019 best biomedical investment case award", which is the industry's recognition and affirmation of the development of TOT in recent years. In the future, TOT will adhere to the business philosophy of "balance between humanity and science and technology", continue to innovate and develop, and make a contribution to China's biomedical industry.